Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study.
about
Heart Disease and Stroke Statistics--2013 Update: A Report From the American Heart AssociationDiabetes and cardiovascular disease: changing the focus from glycemic control to improving long-term survivalHeart disease and stroke statistics--2011 update: a report from the American Heart AssociationHeart disease and stroke statistics--2014 update: a report from the American Heart AssociationHeart disease and stroke statistics--2012 update: a report from the American Heart AssociationHeart Disease and Stroke Statistics-2017 Update: A Report From the American Heart AssociationPreclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor AgonistsThe weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus - an analysis from the SCOUT lead-in period.Impact of data from recent clinical trials on strategies for treating patients with type 2 diabetes mellitus.Severity of obesity and management of hypertension, hypercholesterolaemia and smoking in primary care: population-based cohort study.Effect of glitazones on the progression of coronary artery disease in type 2 diabetes patients.Health utilities of type 2 diabetes-related complications: a cross-sectional study in Sweden.The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus.The medical risks of obesity.Diabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapiesCirculating endothelial microparticles in diabetes mellitusExercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement.Is there a role for coronary artery calcium scoring for management of asymptomatic patients at risk for coronary artery disease?: Clinical risk scores are sufficient to define primary prevention treatment strategies among asymptomatic patients.Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factorsCaloric restriction: powerful protection for the aging heart and vasculature.Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study.Cardiovascular risk prediction in diabetic men and women using hemoglobin A1c vs diabetes as a high-risk equivalent.Effect of diabetes mellitus on sleep qualityEfficacy and safety of empagliflozin as add-on to metformin for type 2 diabetes: a systematic review and meta-analysis.The 30-year cardiovascular risk profile of South Africans with diagnosed diabetes, undiagnosed diabetes, pre-diabetes or normoglycaemia: the Bellville, South Africa pilot studyImpaired cardiometabolic responses to glucagon-like peptide 1 in obesity and type 2 diabetes mellitusEpidemiology of ischaemic heart disease in sub-Saharan Africa.Beyond glycemic control: treating the entire type 2 diabetes disorder.Review of liraglutide versus sitagliptin for patients with uncontrolled type 2 diabetes: more effective HbA 1c reduction with subcutaneous GLP-1 receptor agonist versus an oral DPP-4 inhibitor.Lipid control in patients with diabetes mellitus.Prescribing exercise for individuals with type 2 diabetes: recommendations and precautions.Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?Complementing insulin therapy to achieve glycemic control.Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus.Medical devices and diagnostics for cardiovascular diseases in low-resource settings.Role for combination therapy in diabetic dyslipidemia.Safety and efficacy of the LAP-BAND AP® adjustable gastric band in the treatment of obesity: results at 2 years.Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes.The use of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and hypertension: a focus on African-American populations.Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure.
P2860
Q22306356-21DD04D9-8551-4078-A0A0-1F9E774D9B72Q26827620-B5113F0D-824D-4D66-A5CB-D643BDC40AF1Q29547236-91CEF866-C0C5-4A46-AD2C-919D122EB8D2Q29547691-413BDBC5-20F2-483A-85E9-855763B37E35Q29547909-5849BE0B-1510-4926-830D-DF060DA7EC49Q30238784-8D4AD4B8-BE56-4F8C-A804-A2690D8196D9Q33521451-369A0BA7-33C5-4166-BA59-B5DE7B8B8523Q33534537-F19EE82D-13BC-420D-883C-0AD317AA27D5Q33535235-7520DE19-FA87-4398-B04B-15A00B4E4EC9Q33586657-9B926B03-5C2D-4957-BD24-52B9A39844DFQ33686312-748693D0-B205-4A4B-BE22-F414E6C3CAB9Q33742403-86906C2A-3104-47B0-BAD6-A7CB025A8B57Q33888236-28BB769E-D5C3-45D9-A5C6-5306EBF4D950Q33888248-843D2703-822C-4754-8D72-8A8665F3ECE8Q33949425-0A39A8E5-E154-4FE6-AB90-E689CF899558Q33996570-CE5444E9-7D83-4F72-B3F8-B1C5DE53502CQ34024860-11ED5A3B-C32F-4A5D-A90F-C619F89F17FAQ34133250-86D02BAD-B4AC-44B1-B85C-13F6DD18033FQ34133889-10B8AFD4-0782-4855-8FA2-034C81492601Q34207941-6D884812-0164-43B7-BE63-1C4FFB82896EQ35117192-21552873-C480-4A32-99B6-13117551636FQ35448877-1DDC80E6-D068-4205-8906-92BADDB5B8DEQ35774101-01C11ECA-65F8-478D-B13E-FFB0104607A4Q35911236-E5F88251-B80A-4B3D-890E-2A21F6DF7377Q37041677-1B6D2C09-81F3-4DB1-B0B4-77339069B7C1Q37065219-D559A5BD-50B5-46D5-85F9-E8D745D0FFDCQ37073773-848483F9-6ADD-4828-8411-FC31DB23D14BQ37612693-7DE7637F-E523-4D44-9874-28E910F55E98Q37791325-D850B8F1-2B31-4C40-95EA-95DCEAF5F272Q37853015-FAB98FEC-1E77-458B-BF08-A2ECFA7DD113Q37889564-CBE7C60E-6D4E-41CE-92A8-B59ED5493DD5Q38005223-00E92538-B531-47F3-9A0A-576C56494B7DQ38116766-FD2346CE-9B9F-410E-858F-C7188537BD34Q38151450-6B7C1628-6130-487D-9E5B-4FAEDB6F9C70Q38258016-947041EF-80B9-4669-BB0A-8A745771583BQ38430793-3D30C9BA-2152-4E74-A01A-2A950FCAB598Q38465525-B1B275C9-0754-4727-BF07-35A833D37986Q38783203-65763F34-7B5F-4C2D-8EE7-E1FF5F3D40D1Q38870752-D800D3E5-9F15-4DCD-B5A9-8717B126904FQ39013664-DAE2AC69-EAC6-4AFD-9E1A-71237E943383
P2860
Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Lifetime risk of cardiovascula ...... in the Framingham heart study.
@ast
Lifetime risk of cardiovascula ...... in the Framingham heart study.
@en
type
label
Lifetime risk of cardiovascula ...... in the Framingham heart study.
@ast
Lifetime risk of cardiovascula ...... in the Framingham heart study.
@en
prefLabel
Lifetime risk of cardiovascula ...... in the Framingham heart study.
@ast
Lifetime risk of cardiovascula ...... in the Framingham heart study.
@en
P2093
P2860
P356
P1433
P1476
Lifetime risk of cardiovascula ...... in the Framingham heart study.
@en
P2093
Caroline S Fox
Nina P Paynter
Peter W F Wilson
Ralph B D'Agostino
P2860
P304
P356
10.2337/DC08-0025
P407
P577
2008-05-05T00:00:00Z